Genetron Holdings's net income is $-800M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Dec 2022
Trailing 12 months ending Dec 2022
Loading...
Loading...
The latest net income for GTH is $-800M as of December 2022. That compares with $-500M in the prior-year period — down 60.9% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Genetron Holdings's historical trend and sector peers before judging valuation or financial health.
Over the past year, GTH's net income moved from $-500M to $-800M — a 60.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Genetron Holdings's operating scale or balance-sheet position.
Against Healthcare companies, GTH currently prints $-800M for net income, while the sector average sits near $16B. That is roughly 104.9% below the sector mean. Large gaps often invite a closer look at Genetron Holdings's growth, margins, and balance sheet.
A net income figure of $-800M for GTH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.
After noting GTH's net income ($-800M), review year-over-year change from $-500M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.